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We have previously described the use of a double coated agarose-agarose porcine islet macrobead for the treatment of type I diabetes
mellitus. In the current study, the long-term viral safety of macrobead implantation into pancreatectomized diabetic dogs treated
with pravastatin (𝑛 = 3) was assessed while 2 dogs served as nonimplanted controls. A more gradual return to preimplant insulin
requirements occurred after a 2nd implant procedure (days 148, 189, and >652) when compared to a first macrobead implantation
(days 9, 21, and 21) in all macrobead implanted animals. In all three implanted dogs, porcine C-peptide was detected in the blood
for at least 10 days following the first implant and for at least 26 days following the second implant. C-peptide was also present in
the peritoneal fluid of all three implanted dogs at 6 months after 2nd implant and in 2 of 3 dogs at necropsy. Prescreening results
of islet macrobeads and culture media prior to transplantation were negative for 13 viruses. No evidence of PERV or other viral
transmission was found throughout the study. This study demonstrates that the long-term (2.4 years) implantation of agaroseagarose encapsulated porcine islets is a safe procedure in a large animal model of type I diabetes mellitus.

1. Introduction
In Type I diabetes, the insulin-producing islets of Langerhans,
scattered throughout the pancreas, are selectively destroyed
by an apparent autoimmune process. Daily and often multiple
injections of exogenous human recombinant insulin are the
current standard of care. Despite continual advances in
insulin therapy and the fact that some patients have now
survived for more than 50 years with insulin therapy, the
quality of life can be difficult owing to the nonphysiological
delivery of an insulin bolus. The transplantation of the entire
human pancreas from a deceased organ donor provides
another therapeutic option for diabetic patients, especially,

for those patients already receiving immunosuppressive therapy for a kidney allograft [1]. Alternatively, the insulinproducing islets can be isolated from the majority of the
pancreas and transplanted alone as free islets [2]. As noted
above, a necessary component of the transplantation of
an allogeneic pancreas or the islets alone is the need for
lifelong immunosuppressive therapy. Because complications
from such immunosuppressive therapy can include increased
susceptibility to infections, malignancy, neurotoxicity, and
nephrotoxicity, allotransplantation must be carefully considered and is often not suitable for young patients [3]. Further,
the availability of human donor pancreas is extremely limited
with only about 2,000 pancreas donors per year [4]. Worse,
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only about 16% of procured pancreases meet the criteria for
transplantation and less than 3% are used for islet isolation
[4, 5].
To overcome the major hurdles of organ availability and
immunosuppression, we have reported the ability of porcine
islets, encapsulated in an agarose-agarose macrobead, to
restore normoglycemia in diabetic animal models [6]. The
use of pigs as an islet source provides an unlimited number of
organs for islet isolation and encapsulation. Further, porcine
insulin is nearly identical to human insulin, differing in only
a single amino acid and it has been used in the clinic since its
discovery in 1922 [7]. The double layered agarose encapsulation of the porcine islets also provides at least some protection
from recipient immune responses to the xenogeneic islets
and is likely to ameliorate the need for immunosuppressive
therapy. In fact, we have previously shown the porcine
islet macrobeads to enable the discontinuation of exogenous
insulin for more than 6 months (study termination) in
spontaneously diabetic BB rats without immunosuppressive
therapy [6].
The current study was initiated to further investigate
the effects of multiple implantations of encapsulated porcine
islets to pancreatectomized diabetic dogs (𝑛 = 3 dogs that
received islet macrobeads and 𝑛 = 2 dogs that received
exogenous insulin only). Because human diabetic patients
implanted with macrobeads would be chronically exposed to
porcine islets, we further set out to assess the viral safety of the
macrobeads before implantation and also screened various
canine tissues for evidence of viral transmission after more
than 2 years of porcine islet macrobead exposure.

2. Materials and Methods
2.1. Animals. A total of six male devocalized Beagle dogs
(Ridgelan Farms, Inc., Mount Horeb, WI) were received at
approximately 20 weeks of age. The dogs were individually
housed in stainless steel cages, 32 W × 42 L × 32 H, with
rubber-coated mesh flooring and a stainless steel platform,
32 × 40 . Science Diet Growth (Hill’s, 6730) was provided
twice daily and clean municipal water provided ad libitum.
Viokase (Henry Schein, 9758341) powder was added to food
at a dose of 1 tsp/meal following pancreatectomy. Room temperature was maintained at 18–28∘ C with relative humidity
of 30–70%. A 12-hour light cycle was maintained throughout
the study with lights on at 0700 hours. All study protocol
procedures were approved by The Rogosin Institute Animal
Care and Use Committee (IACUC). The Rogosin InstituteXenia Division animal facility holds Full Accreditation status
awarded by the Association for Assessment and Accreditation
of Laboratory Animal Care, International (AAALAC, Int.).
2.2. Isolation of Porcine Islets and Production of Porcine Islet
Macrobeads. Donor islets were prepared from Newsham
sows over two years of age and with multiple parities. After
electrical stun and exsanguination (Bob Evans Farms, Xenia,
OH), pancreata were retrieved and transported to the islet
isolation laboratory in cold Hank’s balanced salt solution
(HBSS; Mediatech, 21-020) on ice. Warm ischemia times
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averaged 12.26 minutes while cold ischemia times ranged
from 30 minutes to one hour. Islet isolation was carried out
as previously described [6]. Briefly, after trimming the gland
of fat and connective tissue, the main pancreatic duct was
cannulated and injected with HBSS containing 2.0 g/L collagenase P (Roche, 11213873001) and 0.01 g/L DNase (Sigma
Aldrich, D5025). Twice the gram weight of the pancreas (in
mL) was perfused through the pancreatic duct at a rate of
50 mL/min at 18∘ C. Islets were purified on discontinuous
Eurocollins (Mediatech, Inc., 99-408)-Ficoll (Sigma Aldrich,
F9378) gradients of densities 1.105 g/cm3 , 1.095 g/cm3 , and
1.055 g/cm3 in 50 mL polystyrene conical tubes. The tubes
were centrifuged at 2000 RPM, and islet-containing layers
were manually collected. 500 islet equivalents were encapsulated in each agarose-agarose macrobead as previously
described [6]. Islet macrobeads were maintained in RPMI
containing 2.5% porcine serum (Mediatech, 35-041) and
1% antibiotic/antimycotic (A/A; Gibco Life Technologies,
15240) in an atmosphere of 3–5% CO2 and air at 36–38∘ C.
Macrobeads were examined for uniformity, collected the
day prior to implant, and were aliquoted to 175 mL conical
tubes. A maximum of 400 macrobeads per tube were stored
overnight at room temperature (18–28∘ C) in RPMI (Gibco
Life Technologies, 22400) containing 1% A/A.
2.3. Microbiological and Viral Screening. Prior to islet macrobead implantation, representative samples of macrobeads
and culture media were sent to MicroTest Laboratories, Inc. (Agawam, MA) for product bioburden testing
(ANSI/AAMI/ISO 11737-1 Part 1); see Table 1. Macrobeads
were aseptically crushed and extracted with Fluid D (EMD
Millipore, 1.46483.0006) while the culture media was tested
as supplied. Using USP ⟨61⟩ membrane filtration, each sample was filtered onto a 0.45 𝜇m membrane (EMD Millipore,
HVLP), which was then transferred to tryptic soy agar
(TSA) plates and cultured at 32.5∘ C ± 2.5∘ C for 3–5 days
(aerobic, anaerobic, and aerobic spore formers). Additional
samples were filtered onto 0.45 𝜇m membranes, which were
transferred to Sabouraud dextrose agar (SDA) plates and
incubated at 22.5∘ C ± 2.5∘ C for 5–7 days (yeast and mold).
A USP ⟨62⟩ microbial limits test for Salmonella sp. was also
performed by incubation of samples in lactose broth for
48 hours at 30–35∘ C, aliquoted 1 mL/tube to SC/TT tubes,
followed by an additional 24 hours at 32.5∘ C ± 2.5∘ C. Upon
completion of incubation, contents were streaked to brilliant
green agar (BGA), xylose lysine desoxycholate (XLD) agar,
and bismuth sulfite (BS) agar plates for 48 hours at 32.5∘ C
± 2.5∘ C. All bioburden testing included negative media
controls and appropriate positive media controls (Escherichia
coli [ATCC #11229], aerobic; Clostridium sporogenes [ATCC
#11437], anaerobic; Bacillus subtilis [ATCC #6633], aerobic
sporeformer; Candida albicans [ATCC #10231] yeasts and
molds). Colonies were counted using a Reichert Quebec
darkfield colony counter. For each class of organism, the total
recoverable bioburden as CFU/SIP was calculated (culture
media SIP = 5 mL per category; macrobead SIP = 1 bead).
Culture media and islet macrobeads were also sent
to Iowa State University, Veterinary Diagnostic Laboratory (VDL; Ames, IA) for additional microbiological
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Table 1: Preimplant microbiological and vial screening of porcine islet macrobeads.
Test description
Total product bioburden testing

Salmonella sp. screening

Sterility

Mycoplasma

Bacterial endotoxin
Porcine reproductive and respiratory syndrome virus (PRRSV)
Swine influenza virus (SIV)
Porcine endogenous retrovirus (PERV)
Porcine enterovirus (PEV)
Porcine respiratory corona virus (PRCV)
Transmissible gastroenteritis virus (TGEV)
Porcine circovirus types 1 and 2 (PCV)
Porcine lymphotropic herpes virus type-1 (PLHV-1)
Swine hemagglutinating encephalomyelitis virus (sHEV)
Porcine parvovirus (PPV)
Porcine cytomegalovirus (PCMV)
Mycoplasma hyopneumoniae
Pseudorabies virus (PRV)
Encephalomyocarditis virus (EMCV)
Rotavirus (type A)
Chlamydia spp.

testing including porcine virology prior to macrobead
implantation, as summarized in Table 1. Porcine virology tests included: porcine reproductive and respiratory
syndrome virus (PRRSV; RT-PCR using Qiagen, 282315),
swine influenza virus (SIV; RT-PCR using Qiagen, 282615),
porcine endogenous retrovirus (PERV; RT-PCR) [8], porcine
enterovirus (PEV; RT-PCR) [9], porcine respiratory corona
virus (PRCV; RT-PCR using Qiagen, 283615), transmissible
gastroenteritis virus (TGEV; RT-PCR using Qiagen, 283615),
porcine circovirus (PCV; PCR) [10], porcine lymphotropic
herpes virus type-1 (PLHV-1; PCR) [11], swine hemagglutinating encephalomyelitis virus (sHEV; RT-PCR) [12],
porcine parvovirus (PPV; PCR) [13], porcine cytomegalovirus (PCMV; PCR) [14], Mycoplasma hyopneumoniae (PCR)
[15], pseudorabies virus (PRV; virus isolation), encephalomyocarditis virus (EMCV; virus isolation), group A rotavirus
(antigen capture ELISA), and Chlamydia spp. (antigen capture ELISA). Each RT-PCR/PCR assay included a positive
control, a no template control, and was performed according
to standard operating procedures of VDL.

Testing facility
Microtest
Laboratories,
Inc.
Microtest
Laboratories,
Inc.
Microtest
Laboratories,
Inc.
Microtest
Laboratories,
Inc.
Microtest
Laboratories,
Inc.
VDL
VDL
VDL
VDL
VDL
VDL
VDL
VDL
VDL
VDL
VDL
VDL
VDL
VDL
VDL
VDL

Methodology
ANSI/AAMI/ISO 11737-1
USP ⟨61⟩ membrane
filtration
USP ⟨62⟩
USP ⟨71⟩ membrane
filtration
Direct cultivation methods
Cell culture methods
Kinetic chromogenic
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR (Qiagen 283615)
RT-PCR (Qiagen 283615)
Multiplex PCR
PCR
RT-PCR
PCR
PCR
PCR
Virus isolation
Virus isolation
Antigen capture ELISA
Antigen capture ELISA

At the time of the surgical procedure for the second
macrobead implant (day 215 post-1st implant), or sham
surgery for non-implant controls, white blood cells and
biopsies of mesenteric lymph node and tonsil were collected from all study animals and immediately snap-frozen.
Samples were shipped on dry-ice to BioReliance (Glasgow,
Scotland) for assessment of PERV by quantitative real-time
PCR (qRT-PCR). The appropriate controls including: positive
controls (negative control nucleic acid spiked with viral target
sequence), post-extraction spike controls (to assess target
specific PCR inhibition), exogenous internal positive controls
(to establish that all negative PCR results were truly negative
and not due to failed amplification), no-template controls
(to monitor aerosol and reagent contamination), negative
controls (to monitor reagent contamination), and sentinel
extraction controls (to assess possible airborne sample to
sample cross-contamination) were conducted in triplicate
with each assay.
At necropsy, samples of retrieved islet macrobeads and
swabs of the peritoneal cavity were sent for Sterility testing
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per USP ⟨71⟩ via membrane filtration and product immersion to MicroTest Laboratories, Inc. Using a direct cultivation and cell culture method, retrieved islet macrobeads
were screened for the presence of Mycoplasma (MicroTest
Laboratories, Inc., per the FDA Points-To-Consider in the
Characterization of Cell Lines used to produce Biologicals).
Macrobeads were also screened for the presence of Bacterial
Endotoxin by MicroTest Laboratories, Inc. following the
procedure depicted in the FDA 1987 Guidance for Bacterial
Endotoxin Testing.
Samples of retrieved macrobeads, white blood cells,
bone marrow, mesenteric lymph node, small intestine, liver,
kidney, heart, lung and central nervous system (brain) were
collected aseptically, snap-frozen, and sent to BioReliance
for viral screening. The six different viruses screened for
in necropsy tissues are shown in Table 2. Virus selection
was based on their ubiquitous nature in swine (sEMCV,
PLHV, sHepE, PCV, PCMV, and PERV), or their specific
presence in source animals (PCV, PERV), or their transspecies infectivity potential (sEMCV, PLHV, sHepE, PCMV,
and PERV), and clinical significance (all). Samples were
assessed by qRT-PCR for the presence of specific porcine
nucleic acid sequences from both control dogs and islet
macrobead implanted dogs. Probe sequences used in the
viral screening process are proprietary but are available upon
specific request. Testing was conducted in accordance with
the Principles of Good Laboratory Practice and under the
regulations described in the United States Federal Register 21
CFR Part 58.
2.4. Surgical Procedures. Animals were sedated with acepromazine at a dose of 0.05 mg/kg IM (Henry Schein,
356-7290) and anesthetized with ketamine at a dose of
5 mg/kg (Fort Dodge Animal Health, 9952949), diazepam
at a dose of 1 mg/kg (Butler, GNR04054) and isoflurane
gas at 1–3% (Henry Schein, 982-2413). During surgery all
animals received buprenorphine (Butler, GNR02300) at doses
of 0.005–0.020 mg/kg IM during surgery and every 8–12
hours after surgery, continuing for 2-3 days; and cefotaxime
(claforan antibiotic; Henry Schein, 852-1633) at a dose of
20 mg/kg IV during and 8 hours after surgery. At implant,
the abdominal, subcutaneous, and cutaneous incisions were
closed with 3-0 vicryl (Ethicon, J333), 3-0 vicryl, and 3-0
nylon (Ethicon, J669) sutures and 6.70 mm × 3.90 mm precise
skin staples (3M Health Care), respectively. At pancreatectomy, the abdominal, subcutaneous, and cutaneous incisions
were closed with 2-0 vicryl (Ethicon, J332), 4-0 polymend
(Veterinary Products Laboratories, V-397-1), and 3-0 nylon
(Ethicon, J669H) sutures, respectively.
Fourteen weeks following arrival, all animals underwent
pancreatectomy for the induction of insulin-dependent diabetes. The pancreas was exposed by a peritoneal midline incision and removed with blunt dissection. Following induction,
animals were maintained on Humulin 70/30 insulin (Eli Lilly,
029363) at doses to attempt morning (0900 hr) and evening
(1800 hr) normoglycemia. At the time of pancreatectomy, the
majority of the omentum was also removed.
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2.5. Porcine Islet Macrobead Implantations. On day 81 after
pancreatectomy, three animals received a 1st implant of
porcine islet macrobeads at a dose equivalent to 4× daily
insulin requirements. The three dogs that received the
first implant underwent a second implant (dose = 3×) of
islet macrobeads 215 days after the 1st implant. Insulin
requirements of recipients and the corresponding number of
porcine islet macrobeads received are given in Table 3. At the
time of the second implant, nonimplanted control animals
received a sham surgery. Animals receiving porcine islet
macrobeads were started on pravastatin (80 mg/day; Teva
Pharmaceuticals) 48 hr prior to a 1st implant and continued
daily throughout the course of study.
Because the in vivo environment of the dog abdomen
would likely impair insulin production from implanted
macrobeads as compared to the carefully controlled in
vitro culture environment, we opted to implant dogs with
enough macrobeads to provide 4 times (4× dose for the 1st
implant) or 3× (3× dose for the 2nd implant) the amount
of each dog’s daily exogenous insulin requirement. Insulin
production during a 24 hr period of in vitro culture was
determined once a week prior to macrobead implantation
for each batch of islet macrobeads (see below) so that an
average quantity of insulin secretion per macrobead in the
four weeks prior to each implant could be calculated (see
Table 3). The daily exogenous insulin requirements of each
macrobead implanted dog were multiplied by 4 (first implant)
or 3 (second implant) and enough macrobeads implanted
to provide either a 4× or 3× dose of insulin. As insulin
production varies with every batch of islet macrobeads,
each preparation of islet macrobeads was evenly divided
amongst the different recipient dogs such that each animal
received a proportion of each batch of macrobeads based
on exogenous insulin requirements. For the first implant,
each dog received 1118–1380 porcine islet macrobeads with
a total macrobead weight of 0.31–0.36 kg. For the second
macrobead implant each dog received 1096–1904 porcine islet
macrobeads weighing 0.29–0.49 kg. Average macrobead age
(time after isolation and encapsulation) was 13.8 weeks for all
dogs at the time of the first implant and 14.1 weeks for the
second implant.
A peritoneal midline incision was made and the site
of pancreatectomy was examined for the presence of any
residual pancreatic tissue just prior to placing the macrobeads
into the peritoneal cavity. Immediately prior to implant,
macrobeads were washed three times with RPMI containing
1% A/A and were gently placed into the peritoneal cavity
by use of a sterile plastic spoon. As needed, animals were
manually fed Hill’s Prescription Diet A/D (5670), Hill’s
canned Science Diet Growth (6680), and/or Nutri-Cal (Evsco
Pharmaceuticals, 01311) to maintain normoglycemia during
the first 24–48 hours after implant.
2.6. Clinical Observations. Individual animal medical observations were recorded daily throughout the study. Observations included appetite, bowel movements, body weight,
blood glucose (Accu-Chek Simplicity BG monitor and
Chemstrips; maximum value of 600 mg/dL: Roche Diagnostics), urine glucose, and insulin therapy.
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Table 2: Microbiological screening performed at necropsy on retrieved islet macrobeads and study animal samples and tissues.
Test description

Testing facility

Sterility

Microtest Laboratories, Inc.

Mycoplasma

Microtest Laboratories, Inc.

Bacterial endotoxin

Methodology
USP ⟨71⟩ membrane
filtration
Direct cultivation methods
Cell culture methods

Microtest Laboratories, Inc.

Kinetic chromogenic

Porcine endogenous retrovirus (PERV)

BioReliance

qRT-PCR

Porcine circovirus types 1 and 2 (PCV)

BioReliance

qRT-PCR

Porcine lymphotropic herpes virus type-1 (PLHV-1)

BioReliance

qRT-PCR

Swine hepatitis E virus (sHepE)

BioReliance

qRT-PCR

Porcine cytomegalovirus (PCMV)

BioReliance

qRT-PCR

Swine encephalomyocarditis virus (sEMCV)

BioReliance

qRT-PCR

Table 3: Individual dog insulin requirements and islet macrobead information at first and second implant.
Porcine islet macrobead information

First implant

Second implant

Animal ID

Body weight
(kg)

Daily insulin
requirement (IU)

Daily insulin
production
(IU/bead)

FOX-1

12

14

0.046

Number of
macrobeads
implanted
1209

Total daily
Weight of
insulin (IU)
implanted
from implanted macrobeads
macrobeads
(kg)
55.6

0.32

HSX-1

11

13

0.046

1118

51.4

0.31

KOX-1

12

16

0.046

1380

63.5

0.36

FOX-1

13

15

0.042

1096

46.0

0.29

HSX-1

14

26

0.042

1904

79.9

0.49

KOX-1

14

16

0.042

1170

49.1

0.30

2.7. Intraperitoneal Sample Collections. Intraperitoneal fluid
was collected during a glucose/arginine challenge procedure
and samples tested for the presence of porcine C-peptide
as follows. Following light anesthesia, an IV catheter was
inserted into the peritoneal cavity and 10 mL/kg of a 16.7 mM
glucose and 5 mM arginine solution were injected. This infusion procedure was carried out for two of the implanted dogs
(FOX-1 and KOX-1). HSX-1 received the glucose/arginine
challenge, though intraperitoneal fluid was only collected
from the initial 30–35 minute timepoint following challenge.
2.8. Porcine Insulin and C-Peptide Assays. Standard radioimmunoassays from Linco Research, Inc. were used for the
detection of porcine insulin (PI-12 K, sensitivity of 2 𝜇U/mL)
and porcine C-peptide (PCP-22 K, sensitivity of 0.1 ng/mL).
Assays were run according to the manufacturer’s instructions
with samples in duplicate and reference, standards, and
controls in triplicate.
2.9. Necropsy. Complete necropsies were performed on day
867 after 1st implant of porcine islet macrobeads. Following
anesthesia, the collection of blood, and exsanguination, macrobeads were randomly retrieved for virology (𝑛 = 60; snap
frozen, 6 macrobeads/tube), histopathology (𝑛 = 50; fixed

in 10% neutral buffered formalin (NBF), 5 macrobeads/tube)
or microbiology (𝑛 = 12; snap frozen, 6 macrobeads/tube).
Macroscopic observations were noted, and major organ
systems and tissues photographed. Weights of major organs
were recorded. Tissue samples, including porcine islet macrobeads, were sent to BioReliance for viral screening or sent
to Pathology Associates International (PAI, A Charles River
Company; West Chester, OH) for histopathology.
2.10. Histopathology. At the time of pancreatectomy, both
pancreas and omentum were fixed in 10% NBF for 24 hrs,
washed, and stored in 70% ethanol. At necropsy, the following tissues were collected, fixed as above, and sent to
PAI: heart, spleen, liver, kidneys, brain, testes, duodenum,
jejunum, ileum, mesentery, adrenal glands, stomach, lungs,
diaphragm, abdominal musculature, bone (sternum), spinal
cord, sciatic nerve, epididymus, eyes, submandibular lymph
nodes, bladder, muscle (thigh), thymus, thyroid, and parotid
salivary gland. Tissues were embedded in paraffin, and 5 𝜇m
sections were stained with haematoxylin and eosin (H&E).
Samples were analyzed by a Diplomat of the American
College of Veterinary Pathology, and the macroscopic and
histopathological findings were documented. All histopathology was performed according to standard operating procedures of PAI.
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3. Results
3.1. Preimplant Macrobead Screening. Culture media and
macrobead samples were found to be negative for bacterial growth and Salmonella sp. throughout the observation
periods. Prior to the first macrobead implant, 6 macrobead
preparations and samples of the 6 corresponding culture
medias were screened for a panel of porcine viruses and
microbial agents as described above and shown in Table 1. All
macrobead and media samples tested positive by RT-PCR for
PERV. All other macrobead and media samples were negative
for the screened viruses.
Prior to the second macrobead implant, 2 randomly
selected macrobead preparations and samples of the 2 corresponding culture media were screened for the same panel
of porcine viruses and microbial agents as the first implant
macrobeads. Macrobead and media samples were positive for
PERV and negative for all other screened agents.
3.2. Insulin Requirements and Individual Blood Glucose. Following pancreatectomy, insulin requirements were adjusted
for each dog over a 4-week period. The dogs were considered
to have exogenous insulin requirements established by week
4after induction. Mean daily insulin requirements between
weeks 4-5 ranged from 11 to 20 IU per dog (Figure 1).
The three implanted dogs remained insulin-free for 12–
14 days after the first implant of islet macrobeads, at which
time the animals were started on 4 units of insulin in the
morning and 4 units in the evening in response to rising
blood glucose levels (Figure 1(b)). Exogenous insulin was
gradually increased over the next 1-2 weeks until blood
glucose levels stabilized. Preimplant insulin requirements
were reestablished by 3 weeks following transplantation. The
2 control dogs did not undergo macrobead implantation or
sham surgery at the time of the first implant.
Following the second islet macrobead implant, the three
implanted dogs began exogenous insulin therapy on day 9
(KOX-1) or 21 (FOX-1 and HSX-1). Presecond implant insulin
requirements were reestablished for the dogs after the 2nd
implant on day 148 (FOX-1), day 189 (KOX-1), and >day 652
(HSX-1) after 2nd implant.
3.3. Serum and Intraperitoneal Porcine C-Peptide. Random,
nonfasting porcine C-peptide was not detected in the
serum of any study animals before pancreatectomy or prior
to macrobead implantation nor in the two control dogs
throughout the study. Serum porcine C-peptide was, however, detected in the three macrobead implanted dogs after
transplantation (Figure 2(a)). FOX-1 showed only minimal
levels of C-peptide following both implant procedures with
levels ranging from 0.1–0.2 ng/mL. C-peptide levels up to
0.31 ng/mL (HSX-1) and 0.29 ng/mL (KOX-1) were found 1213 days following the first implant. On days 21-22 following
2nd implant, C-peptide levels of 0.34 ng/mL (HSX-1) and
0.45 ng/mL (KOX-1) were found. By days 82-83 post 2nd
implant, only HSX-1 had any evidence of circulating porcine
C-peptide (0.18 ng/mL).
Porcine C-peptide was detected in the peritoneal fluid
of all three implanted dogs approximately 3 months prior
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to necropsy during an intraperitoneal glucose/arginine challenge procedure (Figure 2(b)). Serum C-peptide was not
detected at this time in any of the three implanted dogs.
Control animals did not undergo the peritoneal challenge or
fluid collection procedure. At necropsy, porcine C-peptide
was detected in the peritoneal fluid of HSX-1 and KOX-1
(0.41 ng/mL and 0.32 ng/mL, resp.) but not in the peritoneal
fluid from FOX-1.
3.4. Body Weights. All animals lost body weight immediately
after pancreatectomy. Over the next several months, study
animals regained weight and surpassed preinduction levels.
A slight increase in body weight was also observed in the
immediate period following both macrobead implantations,
as a result of macrobead weight and fluid therapy associated
with the surgical procedures.
3.5. Necropsy. Complete necropsies were performed on all
study animals on day 867 after macrobead implant. During
the exploration of the peritoneal cavity it was noted that the
majority of the macrobeads were free-floating and intact.
Macrobeads were occasionally found to be either entangled
in residual omentum tissue or contained within the pelvic
omentum-like tissue (5–10% of macrobeads). Nonetheless,
these entrapped macrobeads were free-floating within their
tissue cavities. Few macrobeads from all three implanted dogs
were also found to be lodged between the lobes of the liver.
Only HSX-1 had any evidence of a broken macrobead(s): a
few agarose macrobead fragments were observed embedded
in a lobe of the liver. No broken macrobeads were observed
in the other two implanted dogs.
Diffuse fibrotic plaques and mesothelial hyperplasia were
common findings on the serosal surface of the abdominal
wall and abdominal tissues. The proliferative lesions were
limited to the serosal surfaces and did not appear to extend
into organ parenchyma cells at sectioning. Macroscopic views
of mesentery from implanted and control dogs were nearly
identical (Figure 3) demonstrating the biocompatibility of the
agarose macrobeads. Various lobes of the liver from all 3
implanted dogs presented with occasional indentations due
to the presence of macrobeads.
3.6. Virology of Animal Samples and Tissues. During the
surgical procedure at the time of second macrobead implant
or sham surgery (control dogs), biopsies of tonsil and mesenteric lymph node and white blood cells were collected from
all study animals for assessment of PERV.
At necropsy, nine tissues (bone marrow, C.N.S (brain),
mesenteric lymph node, small intestine, heart, kidney, liver,
lung, and PBMCs) and islet macrobeads were collected and
screened by PCR for the presence of 6 different viruses. All
tissues were negative for the presence of PCMV, PLHV, PERV,
sHEV1 and sHEV2, and sEMCV. PERV specific sequences
were detected in all islet macrobead samples. In samples from
both control and implanted dogs, low level amplification
signals for PCV were found in a number of different tissues
suggestive of a cross-reaction with canine sequences.
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Figure 1: Blood glucose levels of study animals are shown as an average of daily AM and PM blood glucose levels (open circles). Exogenous
insulin totals are graphed as a sum of daily AM and PM insulin units received (closed squares). Control animals (did not receive porcine islet
macrobeads) are shown in (a) ILX-1 and IWX-1. Animals that received porcine islet macrobeads are shown in (b) FOX-1, HSX-1, and KOX-1.

3.7. Histopathology. Tissues and macrobeads collected at
necropsy were processed and examined by a board-certified
pathologist. Viable islet cells were not found in the macrobeads examined from the three implanted dogs. The

majority of the macrobeads were found to contain amorphous basophilic, mineralized granules. Some macrobeads
were surrounded by a proliferative inflammatory capsule
characterized by a minimal to mild degree of fibrous collagen
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Figure 2: Serum porcine C-peptide levels of macrobead implanted dogs following 1st and 2nd implant [(a): FOX-1 (triangle); HSX-1 (square);
KOX-1 (circle)]. Porcine C-peptide was also detected in the peritoneal fluid of implanted study animals following glucose/arginine challenge.
(b) Porcine-C-peptide was not determined (n.d.) at all timepoints for HSX-1 because fluid was not collected beyond 30–35 minutes.
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Figure 3: Macroscopic images taken at necropsy for a nonimplant control animal [ILX-1; (a), (c)] and a porcine islet macrobead recipient
[HSX-1; (b), (d)]. (a)-(b) were taken at the initial opening. (c)-(d) are images of the mesentery of both animals.

tissue. Peritoneal organs and tissues with a serosal surface had
minimal to mild proliferative and inflammatory lesions. The
lesions were composed of fibrous connective tissue covered
with a thin layer of mesothelium or mesothelial cells. There
were no systemic effects attributable to the presence of the
macrobeads.

4. Discussion
The results of this study demonstrate the safety of transplanting agarose-agarose porcine islet macrobeads in a fully

discordant large animal model as a treatment for insulin
dependent diabetes. Importantly, specific immunosuppressive therapy was not administered, although pravastatin was
given for its mild anti-inflammatory properties. All three
dogs that received porcine islet macrobeads were insulinfree for approximately 2 weeks following the first implant
procedure. Preimplant insulin requirements were reached
over the following week such that by three weeks after
implantation all animals were again on full insulin requirements. Remarkably, the implanted dogs did not reach preinsulin requirements following the second implant, until
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significantly longer periods of time. In fact, one animal
still had not reached preimplant insulin requirements, at
necropsy, on day 652 following 2nd implant.
A significant issue with any xenotransplantation procedure is the possibility of xenozoonosis. In the case of porcine
islets, porcine endogenous retrovirus (PERV) is encoded
throughout the porcine genome, and because it is unlikely
to be removed, this virus has generated considerable attention of the xenotransplantation community and regulatory
authorities (see review by Denner and Tonjes [16]). Although
PERV was shown to infect human cells in vitro [17], there is
no evidence of transmission to humans including farmers,
veterinarians, or abattoir workers, all of whom are exposed
daily to numerous porcine secretions, excretions, blood, and
tissues. More than 80 years of using porcine insulin in
the clinic has also not revealed any transmission of PERV.
Preclinical studies in nonhuman primates have also not
detected any evidence of PERV transmission [18] even with
high dose immunosuppression and high titers of PERV [19].
Also assuring are the negative human clinical findings of
PERV transmission to date including burn patients treated
with porcine skin [20], patients with hemophilia treated with
porcine factor VIII [21], and patients receiving extracorporeal
porcine hepatocyte therapy [22–24], as well as from two
clinical trials of porcine islets following implantation [25, 26].
Nonetheless, the accidental transmission of animal viruses
and PERV in particular mandate a carefully thought out
strategy to manage such risks [27, 28].
The ability of the islet macrobeads to survive extended
culture periods up to at least one year [6] provides ample
opportunity to not only determine the insulin production
from each batch of macrobeads but to also screen the macrobeads for evidence of microbiological and viral pathogens.
We have recently demonstrated the proliferation of macrobead encapsulated porcine insulin-producing cells over the
first few weeks of culture [29]. During this time, insulin
production increases from starting levels and gradually stabilizes. This allows a determination of the precise insulinproducing capacity of encapsulated islets and the subsequent
implantation of a patient-tailored dose of macrobeads to meet
individual insulin demands.
As noted above, the islet macrobeads are also routinely
screened for numerous pathogens prior to implantation
into study animals. Traditional organ allografting techniques
do not allow for the extended testing times required to
assure the absence of xenorelated infectious diseases, and
until now, the promise of islet xenotransplantation has been
largely unrealized by this restraint. The agarose-agarose islet
macrobead affords ample time for extensive microbiological
safety testing. We consider this an advanced technique to
the antemortem screening of donor animals because the
tissue to be transplanted can be tested directly. This is a
significant technological advance and one with the potential
to finally make xenotransplantation a reality. Furthermore,
additional patient safety is obtained by not requiring the
immunosuppression of macrobead recipients [30].
Similar to the findings discussed above, we have not
found any evidence of viral transmission, including PERV,
in diabetic rats implanted with porcine islet macrobeads [6].
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In the current study, viral transmission was also not found
in biopsies of mesenteric lymph node tissue and tonsil tissue
and peripheral blood mononuclear cells on day 215 after the
1st implant (immediately prior to implanting the second dose
of macrobeads).
Additionally, numerous tissues were collected at necropsy
from all study dogs. At this time, islet macrobead implanted
dogs had been exposed to porcine tissue for 2.4 years.
All tissues were found to be negative for the screened
viral sequences although some low level amplification was
observed for PCV in some tissues of all dogs including the
nonimplanted control animals. As low level amplification signals for the PCV target were detected in both negative control
and macrobead implanted animals, it is likely that this finding
is due to a cross-reaction with canine specific sequences.
The negative findings from the extensive viral screening of
the islet macrobeads prior to implantation also support the
notion that porcine islet macrobead implantation, under the
conditions of this study, can be performed safely and does not
result in trans-species viral transmission.
Consistent with a previous study [31], the islet macrobeads were found to be extremely biocompatible. At
necropsy, most islet macrobeads were intact and free-floating
in the peritoneal cavity. Only one animal had any evidence of
a broken macrobead(s). These results demonstrate the ability
of the islet macrobeads to resist breakage in vivo. Perhaps the
most impressive finding at necropsy was the mild degree of
inflammatory reaction in the peritoneal cavity which was not
thought to impair organ function. Furthermore, these data
also demonstrate the capacity of the abdomen to accommodate a large number of macrobeads. Ongoing improvements
in the insulin secretion capacity of each islet macrobead
continue to allow for the implantation of fewer macrobeads
in order to replace exogenous insulin. Finally, current clinical
trials of a similarly sized mouse renal adenocarcinomacontaining agarose macrobead for the inhibition of various
cancers have shown the human abdomen to easily house
several thousand such macrobeads [32, 33].
These data support the feasibility of transplanting
agarose-agarose porcine islet macrobeads as a treatment
strategy for insulin dependent diabetes mellitus. The macrobeads are resistant to breakage and degradation and are
nontoxic and biocompatible. The ability to incubate the
porcine islet macrobeads for extended periods in order to
prescreen the islets for numerous pathogens further advances
the safety profile of this therapy. Critically, no evidence of
viral transmission was observed after long-term implantation
in diabetic study animals.
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